Relative Bioavailability Study of a Tablet Formulation vs. Pediatric Granule Formulation of Dolutegravir 50 mg and Effect of Different Types of Water Plus Infant Formula on the Pediatric Granule Formulation in Healthy Male and Female Volunteers.

Trial Profile

Relative Bioavailability Study of a Tablet Formulation vs. Pediatric Granule Formulation of Dolutegravir 50 mg and Effect of Different Types of Water Plus Infant Formula on the Pediatric Granule Formulation in Healthy Male and Female Volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Nov 2013

At a glance

  • Drugs Dolutegravir (Primary)
  • Indications Herpesvirus infections; HIV infections
  • Focus Pharmacokinetics
  • Sponsors ViiV Healthcare
  • Most Recent Events

    • 25 Nov 2013 Results published in Antiviral Therapy.
    • 08 Mar 2012 Results presented at the 19th Conference on Retroviruses and Opportunistic Infections.
    • 15 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top